Ronnie Shapira-Frommer

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

Ayala Hubert, Helen Mann, Gillian Mitchell, 2016, Gynecologic oncology.

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Ayala Hubert, Gillian Mitchell, Rita K Schmutzler, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Werner Meier, Ignace Vergote, Philipp Harter, 2016, Cancer.